Radioligand Therapies Market Size, Share & Industry Analysis, By Product (Lutetium Lu 177 Vipivotide Tetraxetan, Lutetium Lu 177 Dotatate, and Others), By Indication (Prostate Cancer, Neuroendocrine Tumors, and Others), By Target (Prostate-Specific Membrane Antigen (PSMA), Somatostatin Receptor, and Others), By End User (Tertiary Care Academic/Comprehensive Cancer Centers, Specialized Nuclear Medicine Centers, and Others), and Regional Forecast, 2026-2034